Sandusky, OH, April 8, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
PAOG is working with Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval. PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.
Last month, PAOG released a comprehensive update on its CBD Nutraceutical Development Program with the first PAOG CBD Nutraceutical products, packaged by Alkame Holdings, Inc. (OTC Pink: ALKM), expected to come to market before the end of this year marketed through North American Cannabis Holdings, Inc. (OTC Pink: USMJ). Next week, on Tuesday, PAOG will release a similar update on its CBD Pharmaceutical Development Program,
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.